the continued next will XXXX strong that and Anika's year a phase and dynamic Sylvia, to year you, pivotal Thank good call. we building drive of flow Welcome while earnings Anika fourth evening, and was deliver as growth. on cash for full our foundation everyone. XXXX earnings to quarter and
are highlights cash toward discipline year shareholders. with full that to ability and of are of our our The an our and to performance XXXX a eye direct generating company and quarter value our strict snapshot manage business capably financial undergoing within elements control a transformation. the fourth a returning Our results
near-term growth challenges legacy Anika am company on More continue producing focus future. we our the importantly, remains our to to and Overall, relating initiatives in address a cash profitable and I structure to confident very of strategic growth contracts.
against company a being innovative vision of executing that therapies. are our delivers commercial orthopedic continuum global a We of strategic
We the we strong And as years. to value foundation assured know are of proposition the strategic next physicians our several patients, earnings ongoing have drive our our and as on opportunities new executing leveraging multiple by over well revenue operational and resources growth and initiatives, our and and shareholders. that I to
progress are a our our which commercial transformation also towards guide into five plan, global year We solid making continued finalizing developing company. will and strategic
that following indicated spoke and While transformative we I the profitability broad of we review beginning XXXX key being drivers details look the our about later forward specific board elements plan, sharing some quarter, our period. to this Through lens, of a that the marked year future our growth. Last approval. people, have of and of pipeline
achieved. we Just look what have at
the in by we new International and Vice of Vice operational a First, international and appointing our evaluate President leadership Operations to of to U.S. our a team improve expanded drive performance. President efficiencies Sales
plans Later bring organization. to new to value added new of directors who X also independent believe will we and I our discuss company. our Board qualified for our Directors We highly strengthen enhanced will drive perspectives additional
the innovative procedures deliver remain hybrid progress new year. launch community years. deploying next series an initial over global of a well developing significant model a for the bone We to completed U.S. positioned delivered our rotator commercial we prototype repair to the for cuff therapy and for treatments regenerative orthopedic several and delivered second toward in to also work surgically repairs first this later regenerative therapy made surgically We our as
products also margin of global product initiatives. related production second of following distribution of quarter and other our voluntary resumed these fourth in from non-safety the this as related recall improved planned We HYALOGRAFT-C We gross saw HYALOMATRIX and in HYALOFAST, the and quarter XXXX.
osteoarthritis and confident in strategic are of our we drive our phase are challenges focused that plan, the incredible have a in make pipeline our capture robust has our tissue on As growth. we of We for cartilage remain delivering product the repair strengths, to and to innovative to refine difference Anika to beyond we a restoration. opportunity finalize the spanning and understand patients. next working pain and regeneration lives solutions management patients
taking the commercial now value we for products increased patients are of and those way new the The users, for product steps physician lines, important shareholders. our management will help and pave over that our control create
pathway we our quarter, in noted the we well leverage ahead, number will team sustained which last including I'd recently extension data, in our strategy to to continues We will discuss about leaders identify study further strengthen I turn I to I for that we Anika our can won't innovation years provide that an profitability drive clinical and As area with FDA with discuss but CINGAL the sheet have execute know the value. update right happen talked X. enhancing from area on met shareholder as data shortly. enhance growth which Please regulatory approval. overnight, to to a product XX-XX Slide the healthy quality balance experienced opportunities and place additional continue the like in and to now CINGAL. have also including as as the the now we growth to
not time ago, from As FDA. written minutes the yet received meeting short we the the meeting have occurred a
has CINGAL it it we conduct before to will Phase a clinical productive III for U.S. While trial clear need discussion, another we obtain become the that can approval believe was we in
did we the CINGAL While obtain U.S. in
in and out order clarity worked are additional the of that to the additional understanding need obtain finalize to study, have did the data clinical outlines needed we on that broad design. While are we be there matters
that gather additional to contingency have discussed were to we clinical calls, have support might our As data outcome this includes approval I and on previous we U.S. planning. aware investors in
expeditious and for We will to work for CINGAL. with path FDA most the approval the pursue agency
As further with the and point the and on obtain be approval timeframe to of time. we alignment potential discussions clinical in details interactions nature, have able trial design, a provide won't at about appropriate cost FDA we parameters, substantive requirements and the trial to
clinical We the with markets continue this safety to together our of the treatment. gathered evidence utility efficacy, believe world trial data real in that clinical the and around novel world demonstrate
our we CINGAL in international in its for Canada further Europe, experience Importantly, opportunity. to strong which continue reinforces conviction market demand and
in Phase the data America. update turn to year-over-year fourth on the year of indication MONOVISC hip pursuing I during expanding protocol we aggressively the CINGAL global full the To as quarter expanding commercial franchise presence the and informed increased III support trial clinical new near-term required international partner end, U.S. our South XXXX, Europe, that growth footprint by to are an conducted revenue study. OA XXXX, analyzing For they discontinued expanded OUS that eight we in of CINGAL the our the After by our interim the and for XX% Asia, business. by now XXXX, distributors will partner. us Africa added revenue orthobiologics and our
by review use We intention data decision to drug regarding We a than has this vetting the osteoarthritis recent the regulatory treating to opportunity the underlying for of for have FDA's medical thoroughly development status as internally. to rather device, the not the had begin intend options examine interim HA yet regulatory including a which decades. our been
like to we with even new do Anika HA product limit market, products, changes the for products environment and potentially challenges barriers for present as pricing. in the believe could benefits the regulatory changes developing such companies the clinical and While established competing positive capabilities may they competition companies development deliver reach stabilize possibly for that increase extensive
from products product More viscosupplements our move strategy X. solution. number nice importantly, This to this Please with cartilage purposefully a HYALOFAST, surgical is newer expanded segue already legacy turn to our pathway. beyond innovative repair Slide that development away has
pursue advanced high to support approval. III to very patients we see accelerate of enrollment trial XX% enrollment for strategies and continue regenerative Phase continuing our physicians to level and among unique treatment. are has a over this in to enthusiasm FDA Patient We
enhance procedure. surgeons properties numerous the fact surgical In how greatly have product noted the
HYALOFAST view the U.S. revenue than size to Conservatively, market for be estimate HYALOFAST future with significant we important greater to potential. an continue We product $X.X as billion annually.
for launch U.S. noted internally to launched Slide we track therapy surgical catalyst our Anika base As it of commercial is first HA domestic under momentous be model. as and surgically the developed This will our year. in for remain hybrid the delivered regenerative first half in this on on X, product repair a procedures our second bone
conferences, Society Sports to launch. meetings advantages critical Surgery Solutions the including the launch, we we their of look Knee known the of at and ISAKOS. towards to Regeneration for Academy feedback Preservation multiple this upcoming American at also medicine Cartilage as to industry as these ICRS; Society, prepare Arthroscopy, surgery we Surgeons, the and of and success forward Orthopaedic orthopedic leaders as community therapy global to Medicine our with we is Engaging showcasing thought As Joint orthopedic look the and move AAOS; known commercial International International Orthopaedic the forward
that opportunity million XXX confident XXX are to bone to we we Importantly, repair. positioned market are estimated on well the million for deliver
fuel in XXXX development anticipate procedures of the Anika. This the initiatives and unique therapy I believe We for our new over growth in organic the summary, over created ongoing call completing portfolio treatment of we regenerative to represents now large delivered to provide our and a more therapy drive be initial $XXX are work to represents our growing the regenerative for repair significant prototype details quarter in be million another early provide growth. This our U.S. growth near surgical million given opportunity potential therapy it cuff XXXX will a complements we this in results product before Further, plans used more the financial full medicine turn our would continuing will fourth of on the each Sylvia? product continuum long-term international for the XXX,XXX products. we launch cuff than addressable both U.S. we next rotator that In the With partial in be focused key become orthobiologics designed thickness a and year, opportunity I'll be global will tears full procedures. develop to Sylvia remainder alone. instrumentation that to is market our several sector. reported XXXX. surgically also a market, about review second franchise. We products rotator can preclinical and to for to and year $XXX years
